These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 11877756

  • 1. Single tumor cell uptake and dosimetry of technetium-99m Fab' or minute anti-CD22 in low-grade B-cell lymphoma.
    Lindén O, Hindorf C, Tennvall J, Segrén S, Wingardh K, Strand SE.
    Cancer; 2002 Feb 15; 94(4 Suppl):1270-4. PubMed ID: 11877756
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
    Shen GL, Li JL, Ghetie MA, Ghetie V, May RD, Till M, Brown AN, Relf M, Knowles P, Uhr JW.
    Int J Cancer; 1988 Nov 15; 42(5):792-7. PubMed ID: 3263328
    [Abstract] [Full Text] [Related]

  • 4. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
    Bonardi MA, French RR, Amlot P, Gromo G, Modena D, Glennie MJ.
    Cancer Res; 1993 Jul 01; 53(13):3015-21. PubMed ID: 7686448
    [Abstract] [Full Text] [Related]

  • 5. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
    Sharkey RM, Behr TM, Mattes MJ, Stein R, Griffiths GL, Shih LB, Hansen HJ, Blumenthal RD, Dunn RM, Juweid ME, Goldenberg DM.
    Cancer Immunol Immunother; 1997 May 01; 44(3):179-88. PubMed ID: 9191878
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA, May RD, Till M, Uhr JW, Ghetie V, Knowles PP, Relf M, Brown A, Wallace PM, Janossy G.
    Cancer Res; 1988 May 01; 48(9):2610-7. PubMed ID: 2451562
    [Abstract] [Full Text] [Related]

  • 7. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
    Tuscano JM, O'Donnell RT, Miers LA, Kroger LA, Kukis DL, Lamborn KR, Tedder TF, DeNardo GL.
    Blood; 2003 May 01; 101(9):3641-7. PubMed ID: 12511412
    [Abstract] [Full Text] [Related]

  • 8. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
    DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C, Moran JK, Popplewell AG, Stephens S, Frost P, Damle NK.
    Blood; 2004 Mar 01; 103(5):1807-14. PubMed ID: 14615373
    [Abstract] [Full Text] [Related]

  • 9. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
    Behr TM, Wörmann B, Gramatzki M, Riggert J, Gratz S, Béhé M, Griesinger F, Sharkey RM, Kolb HJ, Hiddemann W, Goldenberg DM, Becker W.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Initial clinical results with technetium-99m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas.
    Baum RP, Niesen A, Hertel A, Adams S, Kojouharoff G, Goldenberg DM, Hör G.
    Cancer; 1994 Feb 01; 73(3 Suppl):896-9. PubMed ID: 8306276
    [Abstract] [Full Text] [Related]

  • 14. 131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates.
    Lindén O, Tennvall J, Hindorf C, Cavallin-Ståhl E, Lindner KJ, Ohlsson T, Wingårdh K, Strand SE.
    Acta Oncol; 2002 Feb 01; 41(3):297-303. PubMed ID: 12195750
    [Abstract] [Full Text] [Related]

  • 15. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
    Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H.
    Clin Cancer Res; 2005 May 15; 11(10):3879-88. PubMed ID: 15897589
    [Abstract] [Full Text] [Related]

  • 16. CD22-mediated cell adhesion to cytokine-activated human endothelial cells. Positive and negative regulation by alpha 2-6-sialylation of cellular glycoproteins.
    Hanasaki K, Varki A, Powell LD.
    J Biol Chem; 1995 Mar 31; 270(13):7533-42. PubMed ID: 7706300
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin.
    French RR, Hamblin TJ, Bell AJ, Tutt AL, Glennie MJ.
    Lancet; 1995 Jul 22; 346(8969):223-4. PubMed ID: 7542357
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.